Display options
Cite
Wahrle SE, Shah AR, Fagan AM, et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007;2:7doi: 10.1186/1750-1326-2-7.
Wahrle, S. E., Shah, A. R., Fagan, A. M., Smemo, S., Kauwe, J. S., Grupe, A., Hinrichs, A., Mayo, K., Jiang, H., Thal, L. J., Goate, A. M., & Holtzman, D. M. (2007). Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Molecular neurodegeneration, 27. https://doi.org/10.1186/1750-1326-2-7
Wahrle, Suzanne E, et al. "Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms." Molecular neurodegeneration vol. 2 (2007): 7. doi: https://doi.org/10.1186/1750-1326-2-7
Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007 Apr 12;2:7. doi: 10.1186/1750-1326-2-7. PMID: 17430597; PMCID: PMC1857699.
Copy Download .nbib Format: NLM
Share it on

Mol Neurodegener. 2007 Apr 12;2:7. doi: 10.1186/1750-1326-2-7.

Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms.

Molecular neurodegeneration

Suzanne E Wahrle, Aarti R Shah, Anne M Fagan, Scott Smemo, John S K Kauwe, Andrew Grupe, Anthony Hinrichs, Kevin Mayo, Hong Jiang, Leon J Thal, Alison M Goate, David M Holtzman

Affiliations

  1. Department of Neurology, Washington University, St, Louis, MO, USA. [email protected]

PMID: 17430597 PMCID: PMC1857699 DOI: 10.1186/1750-1326-2-7

Abstract

BACKGROUND: Animal studies suggest that brain apolipoprotein E (apoE) levels influence amyloid-beta (Abeta) deposition and thus risk for Alzheimer's disease (AD). We have previously demonstrated that deletion of the ATP-binding cassette A1 transporter (ABCA1) in mice causes dramatic reductions in brain and cerebrospinal fluid (CSF) apoE levels and lipidation. To examine whether polymorphisms in ABCA1 affect CSF apoE levels in humans, we measured apoE in CSF taken from 168 subjects who were 43 to 91 years old and were either cognitively normal or who had mild AD. We then genotyped the subjects for ten previously identified ABCA1 single nucleotide polymorphisms (SNPs).

RESULTS: In all subjects, the mean CSF apoE level was 9.09 microg/ml with a standard deviation of 2.70 microg/ml. Levels of apoE in CSF samples taken from the same individual two weeks apart were strongly correlated (r2 = 0.93, p < 0.01). In contrast, CSF apoE levels in different individuals varied widely (coefficient of variation = 46%). CSF apoE levels did not vary according to AD status, APOE genotype, gender or race. Average apoE levels increased with age by approximately 0.5 microg/ml per 10 years (r2 = 0.05, p = 0.003). We found no significant associations between CSF apoE levels and the ten ABCA1 SNPs we genotyped. Moreover, in a separate sample of 1225 AD cases and 1431 controls, we found no association between the ABCA1 SNP rs2230806 and AD as has been previously reported.

CONCLUSION: We found that CSF apoE levels vary widely between individuals, but are stable within individuals over a two-week interval. AD status, APOE genotype, gender and race do not affect CSF apoE levels, but average CSF apoE levels increase with age. Given the lack of association between CSF apoE levels and genotypes for the ABCA1 SNPs we examined, either these SNPs do not affect ABCA1 function or if they do, they do not have strong effects in the CNS. Finally, we find no evidence for an association between the ABCA1 SNP rs2230806 and AD in a large sample set.

References

  1. Am J Hum Genet. 2003 Nov;73(5):1041-51 - PubMed
  2. Neurology. 1999 Jan 15;52(2):244-8 - PubMed
  3. Neurobiol Aging. 2004 May-Jun;25(5):641-50 - PubMed
  4. Neurology. 2001 Feb 13;56(3):312-6 - PubMed
  5. Circulation. 2001 Mar 6;103(9):1198-205 - PubMed
  6. Am J Med Genet. 2002 Mar 8;114(2):235-44 - PubMed
  7. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15233-8 - PubMed
  8. Genome Res. 2000 Feb;10(2):258-66 - PubMed
  9. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2892-7 - PubMed
  10. Ann Neurol. 2000 Jun;47(6):739-47 - PubMed
  11. Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):1983-9 - PubMed
  12. Atherosclerosis. 2000 Oct;152(2):475-88 - PubMed
  13. Exp Gerontol. 2000 Dec;35(9-10):1343-52 - PubMed
  14. Trends Mol Med. 2002 Apr;8(4):168-73 - PubMed
  15. Neurobiol Dis. 2002 Apr;9(3):305-18 - PubMed
  16. Science. 2002 Jul 19;297(5580):353-6 - PubMed
  17. Hum Mol Genet. 2003 Jan 1;12(1):23-32 - PubMed
  18. Neurobiol Aging. 2003 May-Jun;24(3):421-6 - PubMed
  19. Exp Neurol. 2003 Sep;183(1):4-6 - PubMed
  20. Exp Neurol. 2003 Sep;183(1):249-53 - PubMed
  21. J Mol Neurosci. 2004;23(3):255-62 - PubMed
  22. Atherosclerosis. 2004 Aug;175(2):269-79 - PubMed
  23. J Biol Chem. 2004 Sep 24;279(39):40987-93 - PubMed
  24. J Biol Chem. 2004 Sep 24;279(39):41197-207 - PubMed
  25. Neurosci Lett. 2004 Aug 19;366(3):268-71 - PubMed
  26. Science. 2004 Aug 6;305(5685):869-72 - PubMed
  27. Hum Mol Genet. 2004 Nov 15;13(22):2885-92 - PubMed
  28. J Clin Invest. 2004 Nov;114(9):1343-53 - PubMed
  29. J Biol Chem. 2005 Jul 8;280(27):25754-9 - PubMed
  30. J Biol Chem. 2005 Dec 30;280(52):43224-35 - PubMed
  31. Neurobiol Aging. 2007 Jun;28(6):856-62 - PubMed
  32. J Neurochem. 2006 Aug;98(3):792-800 - PubMed
  33. J Biol Chem. 2006 Nov 24;281(47):36180-6 - PubMed
  34. Neurology. 2007 Feb 27;68(9):666-9 - PubMed
  35. J Lipid Res. 1988 Oct;29(10):1309-25 - PubMed
  36. Ann Neurol. 1988 Jul;24(1):17-22 - PubMed
  37. J Clin Invest. 1981 Oct;68(4):1075-85 - PubMed
  38. Ann Neurol. 1995 Aug;38(2):254-9 - PubMed
  39. Neuroreport. 1994 Dec 20;5(18):2534-6 - PubMed
  40. Hum Genet. 1995 Jan;95(1):39-42 - PubMed
  41. Ann Neurol. 1993 Nov;34(5):752-4 - PubMed
  42. Science. 1993 Aug 13;261(5123):921-3 - PubMed
  43. Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9649-53 - PubMed
  44. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81 - PubMed
  45. Neurology. 1996 Mar;46(3):707-19 - PubMed
  46. Neurosci Lett. 1996 Jul 12;212(2):91-4 - PubMed
  47. Dementia. 1996 Sep-Oct;7(5):273-8 - PubMed
  48. Ann Neurol. 1997 Jun;41(6):716-21 - PubMed
  49. Neurosci Lett. 1997 Jun 27;229(2):85-8 - PubMed
  50. Neurobiol Dis. 1997;4(5):313-28 - PubMed
  51. FEBS Lett. 1998 Jan 9;421(2):105-8 - PubMed
  52. Arch Neurol. 1998 Mar;55(3):326-35 - PubMed
  53. Neurology. 1998 Apr;50(4):961-5 - PubMed
  54. Alzheimer Dis Assoc Disord. 1998 Sep;12(3):198-203 - PubMed
  55. Hum Mol Genet. 1998 Nov;7(12):1887-92 - PubMed
  56. Hum Mol Genet. 1999 Feb;8(2):237-45 - PubMed
  57. Hum Mutat. 2004 Apr;23(4):358-67 - PubMed

Publication Types

Grant support